Phase II Study of Dovitinib and Pilot Study of Fibroblast Growth Factor Receptor Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Previously Treated With Anti-Vascular Endothelial Growth Factor Therapy

Trial Profile

Phase II Study of Dovitinib and Pilot Study of Fibroblast Growth Factor Receptor Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Previously Treated With Anti-Vascular Endothelial Growth Factor Therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 23 Jan 2016 Status changed from active, no longer recruiting to discontinued as results presented at the 2016 Gastrointestinal Cancers Symposium
    • 24 Mar 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Oct 2015, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top